Ensysce cautions psilocybin pilot observations do not establish efficacy
Ensysce Biosciences cautioned that observations from a small, uncontrolled psilocybin pilot should not be interpreted as evidence of efficacy for its CRPS treatment program. Participants received a formulation supplied under Oregon’s psilocybin program, not its CY200 drug candidate. No participants have enrolled in the